MICEK JOHN 4
4 · Jaguar Health, Inc. · Filed Mar 12, 2026
Research Summary
AI-generated summary of this filing
Jaguar Health (JAGX) Director John Micek Receives RSUs & Options
What Happened
John Micek, a director of Jaguar Health, received two compensation awards on December 11, 2025: 7,377 restricted stock units (RSUs) and 7,377 derivative option-type awards. Both grants are shown at $0.00 on the Form 4 (typical for equity awards); no cash purchase or sale occurred. The RSUs convert to common shares upon vesting; the options are derivative awards that vest over time per the grant terms.
Key Details
- Transaction date: December 11, 2025; Form 4 filed March 12, 2026 (filing appears late relative to the transaction).
- Awards: 7,377 RSUs (non‑cash award) and 7,377 derivative/option awards, reported as acquisitions at $0.00.
- Vesting: RSUs vest on December 11, 2026 (one-year cliff per filing). Options vest ratably monthly over 12 months from grant date, contingent on continued service.
- Plan/approval: Grants made under the issuer’s 2014 Stock Incentive Plan and approved by the board on Dec 11, 2025.
- Shares owned after transaction: Not specified in the filing.
- Other notes: Filing includes prior reverse stock splits (60-for-1 in May 2024 and 25-for-1 in Mar 2025) that affect historical share counts.
Context
These are compensatory equity awards to a director (not open‑market purchases or insider sales). RSUs convert to shares only when they vest; options are derivative awards that vest over time and are not the same as an immediate exercised sale. The late filing notifies the market of the grants but may reflect an administrative delay rather than substantive trading activity.
Insider Transaction Report
- Award
Common Stock
[F1][F2][F3][F4][F5]2025-12-11+7,377→ 7,430 total - Award
Stock Option (right to buy)
[F1][F2][F6]2025-12-11+7,377→ 7,377 totalExercise: $1.44Exp: 2035-12-11→ Common Stock (7,377 underlying)
Footnotes (6)
- [F1]Granted pursuant to the issuer's 2014 Stock Incentive Plan.
- [F2]The restricted stock unit and option grants were approved by the issuer's board of directors on December 11, 2025.
- [F3]Each restricted stock unit represents a contingent right to receive one share of the issuer's voting common stock. The restricted stock units vest on December 11, 2026. Vested shares will be delivered to the reporting on the vesting date provided in the grant notice.
- [F4]On May 23, 2024, the issuer effected a 60-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "2024 Reverse Stock Split"). Upon effectiveness of the 2024 Reverse Stock Split, every 60 shares of voting common stock was automatically converted into one share of voting common stock.
- [F5]On March 24, 2025, the issuer effected a 25-for-1 reverse stock split of the issued and outstanding shares of its voting common stock (the "2025 Reverse Stock Split"). Upon effectiveness of the 2025 Reverse Stock Split, every 25 shares of voting common stock was automatically converted into one share of voting common stock.
- [F6]The options will vest ratably on a monthly basis over 12 months from the grant date, so long as the reporting person continues to serve on the board of directors of the issuer and Napo Therapeutics, S.p.A., the issuer's subsidiary, as applicable.